Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mammary Glands, Animal | 13 | 2016 | 46 | 3.530 |
Why?
|
Macaca fascicularis | 37 | 2019 | 389 | 2.930 |
Why?
|
Estradiol | 9 | 2018 | 118 | 1.970 |
Why?
|
Animals | 76 | 2019 | 7297 | 1.860 |
Why?
|
Whole-Body Irradiation | 7 | 2019 | 48 | 1.780 |
Why?
|
Macaca mulatta | 17 | 2019 | 322 | 1.610 |
Why?
|
Isoflavones | 5 | 2013 | 65 | 1.530 |
Why?
|
Soybean Proteins | 5 | 2016 | 64 | 1.490 |
Why?
|
Endometrium | 9 | 2016 | 120 | 1.470 |
Why?
|
Medroxyprogesterone Acetate | 8 | 2012 | 89 | 1.450 |
Why?
|
Postmenopause | 12 | 2013 | 397 | 1.430 |
Why?
|
Radiation Injuries, Experimental | 6 | 2019 | 33 | 1.380 |
Why?
|
Brain Injuries | 2 | 2018 | 94 | 1.180 |
Why?
|
Breast Neoplasms | 8 | 2015 | 666 | 1.150 |
Why?
|
Female | 65 | 2019 | 18114 | 1.150 |
Why?
|
Receptors, Progesterone | 8 | 2015 | 45 | 1.130 |
Why?
|
Breast | 4 | 2009 | 53 | 1.060 |
Why?
|
Estrogens, Conjugated (USP) | 9 | 2013 | 125 | 1.040 |
Why?
|
Soybeans | 4 | 2013 | 25 | 1.010 |
Why?
|
Estrogen Replacement Therapy | 5 | 2012 | 182 | 1.010 |
Why?
|
Sexual Maturation | 4 | 2016 | 26 | 1.000 |
Why?
|
Monkey Diseases | 3 | 2016 | 18 | 1.000 |
Why?
|
Diet | 6 | 2016 | 348 | 0.990 |
Why?
|
Extracellular Matrix | 4 | 2018 | 226 | 0.950 |
Why?
|
Gamma Rays | 3 | 2019 | 24 | 0.890 |
Why?
|
Estrogen Receptor alpha | 7 | 2015 | 50 | 0.890 |
Why?
|
Uterus | 6 | 2015 | 73 | 0.870 |
Why?
|
Ovariectomy | 16 | 2018 | 147 | 0.860 |
Why?
|
Cell Proliferation | 12 | 2019 | 573 | 0.850 |
Why?
|
Gene Expression Regulation | 5 | 2019 | 481 | 0.830 |
Why?
|
Brain | 4 | 2018 | 930 | 0.820 |
Why?
|
Placenta | 4 | 2013 | 63 | 0.760 |
Why?
|
Endometrial Neoplasms | 2 | 2011 | 34 | 0.750 |
Why?
|
Vagina | 2 | 2012 | 46 | 0.750 |
Why?
|
Radiation Injuries | 3 | 2017 | 67 | 0.710 |
Why?
|
Progesterone | 3 | 2009 | 80 | 0.700 |
Why?
|
Endometriosis | 2 | 2018 | 66 | 0.690 |
Why?
|
Contraceptives, Oral | 2 | 2008 | 20 | 0.670 |
Why?
|
Fibronectins | 1 | 2018 | 34 | 0.660 |
Why?
|
Immunohistochemistry | 10 | 2016 | 519 | 0.660 |
Why?
|
Receptors, Estrogen | 8 | 2016 | 89 | 0.650 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2018 | 71 | 0.640 |
Why?
|
Cerebrovascular Circulation | 1 | 2018 | 95 | 0.630 |
Why?
|
Gene Expression | 6 | 2018 | 332 | 0.630 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 145 | 0.610 |
Why?
|
Tamoxifen | 4 | 2014 | 48 | 0.600 |
Why?
|
Norpregnenes | 5 | 2013 | 16 | 0.590 |
Why?
|
Phytoestrogens | 2 | 2016 | 16 | 0.580 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 48 | 0.580 |
Why?
|
Cranial Irradiation | 1 | 2017 | 84 | 0.580 |
Why?
|
Decidua | 1 | 2016 | 17 | 0.570 |
Why?
|
Epilepsy | 1 | 2017 | 59 | 0.570 |
Why?
|
Menopause | 3 | 2011 | 86 | 0.560 |
Why?
|
Random Allocation | 9 | 2018 | 212 | 0.540 |
Why?
|
Uterine Neoplasms | 1 | 2015 | 23 | 0.530 |
Why?
|
Estrogen Antagonists | 2 | 2012 | 14 | 0.530 |
Why?
|
Lip | 1 | 2014 | 8 | 0.520 |
Why?
|
Cleft Lip | 1 | 2014 | 12 | 0.510 |
Why?
|
Cell Differentiation | 2 | 2016 | 436 | 0.510 |
Why?
|
Adenocarcinoma | 2 | 2015 | 301 | 0.500 |
Why?
|
Male | 30 | 2019 | 17768 | 0.500 |
Why?
|
Surgical Flaps | 1 | 2014 | 69 | 0.490 |
Why?
|
Goldenhar Syndrome | 1 | 2013 | 4 | 0.480 |
Why?
|
Facial Paralysis | 1 | 2013 | 7 | 0.480 |
Why?
|
Cognition Disorders | 2 | 2015 | 389 | 0.480 |
Why?
|
Puberty | 1 | 2013 | 8 | 0.470 |
Why?
|
Estrogens | 4 | 2013 | 162 | 0.460 |
Why?
|
Syndecan-1 | 3 | 2012 | 7 | 0.460 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2017 | 1374 | 0.450 |
Why?
|
Genistein | 2 | 2009 | 14 | 0.450 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2014 | 190 | 0.440 |
Why?
|
Humans | 32 | 2019 | 29013 | 0.440 |
Why?
|
Progestins | 2 | 2013 | 18 | 0.440 |
Why?
|
Cognition | 1 | 2016 | 524 | 0.430 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2019 | 76 | 0.430 |
Why?
|
Ki-67 Antigen | 6 | 2015 | 29 | 0.430 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2011 | 10 | 0.410 |
Why?
|
Gene Expression Profiling | 5 | 2015 | 320 | 0.400 |
Why?
|
Sentinel Surveillance | 1 | 2011 | 9 | 0.400 |
Why?
|
Apoptosis | 4 | 2013 | 337 | 0.400 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2009 | 249 | 0.390 |
Why?
|
Respiratory Tract Infections | 1 | 2011 | 41 | 0.390 |
Why?
|
Tracheostomy | 1 | 2011 | 28 | 0.390 |
Why?
|
Trachea | 1 | 2011 | 55 | 0.390 |
Why?
|
Bacterial Infections | 1 | 2011 | 42 | 0.380 |
Why?
|
Endometrial Hyperplasia | 2 | 2013 | 14 | 0.360 |
Why?
|
Mammography | 1 | 2009 | 37 | 0.350 |
Why?
|
Androgens | 1 | 2009 | 22 | 0.350 |
Why?
|
Brain Neoplasms | 1 | 2015 | 587 | 0.350 |
Why?
|
Soy Foods | 1 | 2009 | 5 | 0.340 |
Why?
|
Selective Estrogen Receptor Modulators | 4 | 2013 | 29 | 0.340 |
Why?
|
Anticarcinogenic Agents | 1 | 2009 | 24 | 0.340 |
Why?
|
Testosterone | 1 | 2009 | 47 | 0.340 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2008 | 4 | 0.340 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 6 | 0.340 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2008 | 8 | 0.340 |
Why?
|
Tissue Array Analysis | 1 | 2009 | 34 | 0.340 |
Why?
|
RNA, Messenger | 5 | 2016 | 514 | 0.340 |
Why?
|
Contraceptive Agents, Female | 1 | 2008 | 15 | 0.340 |
Why?
|
T-Lymphocytes | 3 | 2019 | 114 | 0.330 |
Why?
|
Receptors, Androgen | 1 | 2009 | 39 | 0.330 |
Why?
|
Tetrahydronaphthalenes | 1 | 2008 | 7 | 0.330 |
Why?
|
Pyrrolidines | 1 | 2008 | 13 | 0.330 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2008 | 19 | 0.330 |
Why?
|
Transforming Growth Factor beta | 1 | 2008 | 66 | 0.310 |
Why?
|
Transcription, Genetic | 4 | 2019 | 136 | 0.310 |
Why?
|
Disease Models, Animal | 9 | 2015 | 980 | 0.300 |
Why?
|
Social Behavior | 1 | 2007 | 67 | 0.300 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2016 | 155 | 0.300 |
Why?
|
Mammary Neoplasms, Experimental | 3 | 2012 | 25 | 0.300 |
Why?
|
Homeostasis | 2 | 2018 | 127 | 0.290 |
Why?
|
Heart | 2 | 2018 | 161 | 0.290 |
Why?
|
Hormone Replacement Therapy | 6 | 2013 | 86 | 0.280 |
Why?
|
Mice | 13 | 2015 | 2368 | 0.280 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 248 | 0.270 |
Why?
|
Body Weight | 5 | 2016 | 290 | 0.270 |
Why?
|
Pregnancy | 6 | 2013 | 807 | 0.260 |
Why?
|
Motor Activity | 1 | 2007 | 310 | 0.260 |
Why?
|
Proliferating Cell Nuclear Antigen | 3 | 2009 | 13 | 0.250 |
Why?
|
Prostatic Neoplasms | 3 | 2015 | 441 | 0.250 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2015 | 57 | 0.240 |
Why?
|
Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 1007 | 0.240 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2014 | 65 | 0.230 |
Why?
|
Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
Organ Size | 4 | 2018 | 196 | 0.230 |
Why?
|
Insulin Resistance | 2 | 2017 | 449 | 0.230 |
Why?
|
Signal Transduction | 5 | 2014 | 666 | 0.230 |
Why?
|
Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
Histocytochemistry | 3 | 2013 | 30 | 0.230 |
Why?
|
Indoles | 2 | 2013 | 58 | 0.220 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
Time Factors | 6 | 2019 | 1997 | 0.220 |
Why?
|
Genes, erbB-2 | 2 | 2012 | 5 | 0.220 |
Why?
|
Receptors, Calcitriol | 2 | 2012 | 10 | 0.220 |
Why?
|
Gonadal Steroid Hormones | 2 | 2012 | 28 | 0.210 |
Why?
|
Receptors, Steroid | 2 | 2012 | 7 | 0.210 |
Why?
|
Ovary | 3 | 2011 | 54 | 0.210 |
Why?
|
Prostate | 2 | 2015 | 68 | 0.200 |
Why?
|
Guanine Nucleotide Exchange Factors | 2 | 2014 | 12 | 0.200 |
Why?
|
Lactalbumin | 2 | 2012 | 10 | 0.200 |
Why?
|
Caseins | 2 | 2012 | 13 | 0.200 |
Why?
|
Retrospective Studies | 4 | 2016 | 3107 | 0.200 |
Why?
|
Coronary Vessels | 2 | 2012 | 147 | 0.200 |
Why?
|
Pterocarpans | 2 | 2011 | 4 | 0.200 |
Why?
|
Models, Animal | 4 | 2013 | 160 | 0.190 |
Why?
|
Mice, Knockout | 4 | 2015 | 425 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2019 | 6 | 0.180 |
Why?
|
Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
Hematopoietic System | 1 | 2019 | 3 | 0.170 |
Why?
|
Estrogen Receptor beta | 2 | 2009 | 12 | 0.170 |
Why?
|
Myocardium | 2 | 2018 | 170 | 0.170 |
Why?
|
Immunity | 1 | 2019 | 19 | 0.170 |
Why?
|
Coronary Artery Disease | 2 | 2012 | 358 | 0.170 |
Why?
|
Skin Neoplasms | 2 | 2014 | 206 | 0.170 |
Why?
|
Diastole | 1 | 2018 | 90 | 0.170 |
Why?
|
Interleukin-1beta | 1 | 2018 | 41 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 91 | 0.160 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2018 | 36 | 0.160 |
Why?
|
Cell Line | 4 | 2019 | 449 | 0.160 |
Why?
|
Blood Cells | 1 | 2018 | 9 | 0.160 |
Why?
|
Monocytes | 1 | 2019 | 119 | 0.160 |
Why?
|
Placebos | 2 | 2008 | 61 | 0.160 |
Why?
|
Administration, Oral | 2 | 2009 | 169 | 0.160 |
Why?
|
Cross-Over Studies | 2 | 2008 | 93 | 0.160 |
Why?
|
Treatment Outcome | 3 | 2016 | 3099 | 0.150 |
Why?
|
Microvessels | 1 | 2017 | 23 | 0.150 |
Why?
|
Middle Aged | 6 | 2016 | 10805 | 0.150 |
Why?
|
DNA Damage | 1 | 2018 | 88 | 0.150 |
Why?
|
Rats | 4 | 2015 | 1604 | 0.150 |
Why?
|
Macrophages | 2 | 2018 | 188 | 0.150 |
Why?
|
Analysis of Variance | 2 | 2008 | 454 | 0.150 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 98 | 0.150 |
Why?
|
Cytokines | 1 | 2018 | 243 | 0.150 |
Why?
|
Uvula | 1 | 2016 | 2 | 0.150 |
Why?
|
Calcium | 1 | 2018 | 296 | 0.150 |
Why?
|
Palate | 1 | 2016 | 5 | 0.150 |
Why?
|
Pharynx | 1 | 2016 | 10 | 0.150 |
Why?
|
Chemokines | 1 | 2016 | 35 | 0.150 |
Why?
|
Atherosclerosis | 2 | 2013 | 691 | 0.140 |
Why?
|
Toxicology | 2 | 2013 | 6 | 0.140 |
Why?
|
Nerve Tissue Proteins | 1 | 2017 | 118 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2016 | 46 | 0.140 |
Why?
|
Logistic Models | 2 | 2009 | 725 | 0.140 |
Why?
|
Mutation, Missense | 2 | 2014 | 48 | 0.140 |
Why?
|
Receptors, Opioid | 1 | 2016 | 38 | 0.140 |
Why?
|
Neuronal Plasticity | 1 | 2017 | 81 | 0.140 |
Why?
|
Obesity | 2 | 2014 | 1062 | 0.140 |
Why?
|
Down-Regulation | 1 | 2016 | 142 | 0.140 |
Why?
|
Up-Regulation | 1 | 2016 | 183 | 0.140 |
Why?
|
Mammary Glands, Human | 2 | 2015 | 15 | 0.140 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 172 | 0.140 |
Why?
|
Inflammation | 2 | 2016 | 503 | 0.130 |
Why?
|
Spinal Cord | 1 | 2016 | 139 | 0.130 |
Why?
|
Estrogen Receptor Modulators | 2 | 2013 | 23 | 0.130 |
Why?
|
Lymphoid Tissue | 1 | 2015 | 10 | 0.130 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 22 | 0.130 |
Why?
|
Risk Factors | 4 | 2016 | 3509 | 0.130 |
Why?
|
Luminescent Proteins | 1 | 2015 | 24 | 0.130 |
Why?
|
Rats, Inbred F344 | 1 | 2015 | 125 | 0.130 |
Why?
|
Myometrium | 2 | 2014 | 11 | 0.130 |
Why?
|
Citric Acid | 1 | 2014 | 6 | 0.130 |
Why?
|
Primates | 2 | 2012 | 100 | 0.130 |
Why?
|
Hirudins | 1 | 2014 | 19 | 0.130 |
Why?
|
Extracellular Matrix Proteins | 1 | 2015 | 40 | 0.130 |
Why?
|
Chemokine CCL2 | 1 | 2015 | 47 | 0.130 |
Why?
|
Platelet Aggregation | 1 | 2014 | 21 | 0.130 |
Why?
|
Epithelial Cells | 3 | 2013 | 138 | 0.130 |
Why?
|
Myoblasts, Skeletal | 1 | 2015 | 16 | 0.130 |
Why?
|
Blood Platelets | 1 | 2014 | 37 | 0.130 |
Why?
|
Antigens, CD | 1 | 2015 | 100 | 0.130 |
Why?
|
Rotation | 1 | 2014 | 46 | 0.130 |
Why?
|
Prostatic Hyperplasia | 1 | 2015 | 54 | 0.130 |
Why?
|
Muscle, Skeletal | 2 | 2017 | 494 | 0.130 |
Why?
|
Phosphoproteins | 1 | 2015 | 54 | 0.130 |
Why?
|
Heparin | 1 | 2014 | 75 | 0.120 |
Why?
|
Fibrinolytic Agents | 1 | 2014 | 70 | 0.120 |
Why?
|
Urinary Incontinence, Stress | 1 | 2015 | 64 | 0.120 |
Why?
|
Risk | 1 | 2015 | 289 | 0.120 |
Why?
|
DNA Adducts | 1 | 2014 | 13 | 0.120 |
Why?
|
Gene Deletion | 1 | 2014 | 64 | 0.120 |
Why?
|
Glucose | 1 | 2015 | 162 | 0.120 |
Why?
|
Radiography | 1 | 2015 | 353 | 0.120 |
Why?
|
Urethra | 1 | 2015 | 100 | 0.120 |
Why?
|
Transcription Factors | 1 | 2015 | 172 | 0.120 |
Why?
|
Growth Hormone | 2 | 2010 | 13 | 0.120 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 4 | 0.120 |
Why?
|
Rats, Inbred Strains | 1 | 2013 | 45 | 0.120 |
Why?
|
Mast Cells | 1 | 2013 | 17 | 0.120 |
Why?
|
Mice, Inbred Strains | 1 | 2013 | 43 | 0.120 |
Why?
|
Lidocaine | 1 | 2013 | 17 | 0.120 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 46 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2013 | 18 | 0.120 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2013 | 23 | 0.120 |
Why?
|
Toxicity Tests | 1 | 2013 | 11 | 0.120 |
Why?
|
Adenosine | 1 | 2013 | 41 | 0.120 |
Why?
|
Heart Arrest | 1 | 2013 | 39 | 0.110 |
Why?
|
Premenopause | 2 | 2012 | 38 | 0.110 |
Why?
|
Body Composition | 1 | 2015 | 365 | 0.110 |
Why?
|
Pathology | 1 | 2013 | 20 | 0.110 |
Why?
|
Frameshift Mutation | 1 | 2012 | 4 | 0.110 |
Why?
|
Animals, Zoo | 1 | 2012 | 1 | 0.110 |
Why?
|
Receptors, Thyrotropin-Releasing Hormone | 1 | 2012 | 1 | 0.110 |
Why?
|
Receptors, Thyrotropin | 1 | 2012 | 2 | 0.110 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2012 | 2 | 0.110 |
Why?
|
Stem Cell Transplantation | 1 | 2015 | 203 | 0.110 |
Why?
|
Primate Diseases | 1 | 2012 | 2 | 0.110 |
Why?
|
Animals, Wild | 1 | 2012 | 4 | 0.110 |
Why?
|
Mammary Tumor Virus, Mouse | 1 | 2012 | 3 | 0.110 |
Why?
|
Aged | 4 | 2016 | 9462 | 0.110 |
Why?
|
Reperfusion Injury | 1 | 2013 | 43 | 0.110 |
Why?
|
Cell Transformation, Viral | 1 | 2012 | 4 | 0.110 |
Why?
|
Metagenome | 1 | 2012 | 5 | 0.110 |
Why?
|
Reproduction | 1 | 2012 | 10 | 0.110 |
Why?
|
DNA | 1 | 2014 | 204 | 0.110 |
Why?
|
Receptors, LDL | 1 | 2013 | 64 | 0.110 |
Why?
|
DDT | 1 | 2012 | 1 | 0.110 |
Why?
|
Drug Combinations | 2 | 2013 | 85 | 0.110 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2012 | 3 | 0.110 |
Why?
|
Intestines | 1 | 2012 | 54 | 0.110 |
Why?
|
Apolipoproteins E | 1 | 2012 | 97 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2012 | 64 | 0.110 |
Why?
|
Mice, Transgenic | 4 | 2015 | 249 | 0.110 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 273 | 0.110 |
Why?
|
Aggression | 2 | 2012 | 28 | 0.110 |
Why?
|
Skin | 1 | 2014 | 203 | 0.100 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2013 | 145 | 0.100 |
Why?
|
Lactation | 1 | 2011 | 14 | 0.100 |
Why?
|
Choristoma | 1 | 2011 | 17 | 0.100 |
Why?
|
Cyclooxygenase 1 | 1 | 2011 | 23 | 0.100 |
Why?
|
PPAR gamma | 2 | 2008 | 45 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 72 | 0.100 |
Why?
|
Biological Availability | 1 | 2011 | 21 | 0.100 |
Why?
|
Adult | 6 | 2019 | 8391 | 0.100 |
Why?
|
Infant | 1 | 2014 | 967 | 0.100 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 50 | 0.100 |
Why?
|
Child | 3 | 2014 | 2209 | 0.100 |
Why?
|
Bacteriological Techniques | 1 | 2011 | 15 | 0.100 |
Why?
|
Age Factors | 2 | 2011 | 1105 | 0.100 |
Why?
|
Vitamin D | 1 | 2012 | 170 | 0.100 |
Why?
|
Stress, Psychological | 1 | 2013 | 207 | 0.100 |
Why?
|
Betapapillomavirus | 1 | 2010 | 1 | 0.100 |
Why?
|
Skin Diseases, Viral | 1 | 2010 | 4 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2011 | 89 | 0.100 |
Why?
|
Child, Preschool | 2 | 2012 | 1164 | 0.100 |
Why?
|
Data Collection | 1 | 2011 | 163 | 0.100 |
Why?
|
Ethinyl Estradiol | 1 | 2010 | 6 | 0.090 |
Why?
|
Ligaments | 1 | 2010 | 12 | 0.090 |
Why?
|
Janus Kinase 2 | 1 | 2010 | 4 | 0.090 |
Why?
|
Acute Disease | 1 | 2011 | 239 | 0.090 |
Why?
|
Tyrosine | 1 | 2010 | 22 | 0.090 |
Why?
|
Risk Assessment | 2 | 2016 | 1300 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2010 | 35 | 0.090 |
Why?
|
Dietary Supplements | 1 | 2011 | 170 | 0.090 |
Why?
|
Papillomavirus Infections | 1 | 2010 | 52 | 0.090 |
Why?
|
Molecular Structure | 1 | 2009 | 53 | 0.090 |
Why?
|
Hippocampus | 1 | 2011 | 185 | 0.090 |
Why?
|
Drug Antagonism | 1 | 2009 | 1 | 0.090 |
Why?
|
Women's Health | 1 | 2011 | 226 | 0.090 |
Why?
|
Dietary Proteins | 1 | 2009 | 50 | 0.090 |
Why?
|
Follow-Up Studies | 1 | 2014 | 2106 | 0.090 |
Why?
|
Cyclohexenes | 1 | 2009 | 12 | 0.090 |
Why?
|
Vinyl Compounds | 1 | 2009 | 8 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 45 | 0.090 |
Why?
|
Carcinogens | 1 | 2009 | 34 | 0.090 |
Why?
|
Cricetulus | 1 | 2008 | 17 | 0.080 |
Why?
|
Diet Surveys | 1 | 2009 | 56 | 0.080 |
Why?
|
CpG Islands | 1 | 2008 | 44 | 0.080 |
Why?
|
Cricetinae | 1 | 2008 | 58 | 0.080 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 34 | 0.080 |
Why?
|
Reproducibility of Results | 1 | 2011 | 724 | 0.080 |
Why?
|
Drug Evaluation, Preclinical | 3 | 2013 | 58 | 0.080 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 784 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2009 | 87 | 0.080 |
Why?
|
Blood Cell Count | 2 | 2019 | 26 | 0.080 |
Why?
|
Prolactin | 1 | 2008 | 10 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2008 | 93 | 0.080 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 284 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2016 | 855 | 0.080 |
Why?
|
PPAR alpha | 1 | 2008 | 29 | 0.080 |
Why?
|
Cervix Uteri | 1 | 2008 | 21 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 92 | 0.080 |
Why?
|
Caspase 3 | 1 | 2008 | 30 | 0.080 |
Why?
|
Urothelium | 1 | 2008 | 51 | 0.080 |
Why?
|
Hyperplasia | 3 | 2014 | 38 | 0.080 |
Why?
|
Depression | 1 | 2011 | 378 | 0.080 |
Why?
|
Adenoma | 1 | 2008 | 35 | 0.080 |
Why?
|
Fibrosis | 1 | 2008 | 102 | 0.080 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2007 | 8 | 0.080 |
Why?
|
Mice, Inbred BALB C | 3 | 2013 | 160 | 0.080 |
Why?
|
Administration, Intravaginal | 1 | 2007 | 5 | 0.080 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2007 | 5 | 0.080 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2008 | 52 | 0.080 |
Why?
|
Epidermis | 1 | 2007 | 23 | 0.080 |
Why?
|
Keratins | 1 | 2007 | 36 | 0.080 |
Why?
|
Linear Models | 1 | 2008 | 425 | 0.080 |
Why?
|
Hydrocortisone | 1 | 2007 | 61 | 0.080 |
Why?
|
Urinary Bladder | 1 | 2008 | 164 | 0.070 |
Why?
|
Cell Line, Tumor | 3 | 2015 | 680 | 0.070 |
Why?
|
Mice, Inbred C57BL | 3 | 2013 | 711 | 0.070 |
Why?
|
Body Mass Index | 1 | 2009 | 862 | 0.070 |
Why?
|
Aging | 2 | 2009 | 880 | 0.070 |
Why?
|
Liver | 1 | 2008 | 464 | 0.070 |
Why?
|
Alternative Splicing | 2 | 2015 | 28 | 0.060 |
Why?
|
Genes, ras | 2 | 2015 | 26 | 0.060 |
Why?
|
Young Adult | 3 | 2018 | 2398 | 0.060 |
Why?
|
Radiation Dosage | 2 | 2017 | 72 | 0.060 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 20 | 0.060 |
Why?
|
Prospective Studies | 1 | 2008 | 2010 | 0.060 |
Why?
|
Phenotype | 2 | 2016 | 629 | 0.060 |
Why?
|
Adolescent | 3 | 2016 | 3248 | 0.050 |
Why?
|
Lipids | 2 | 2016 | 208 | 0.050 |
Why?
|
North Carolina | 1 | 2016 | 1422 | 0.050 |
Why?
|
Cell Movement | 2 | 2012 | 161 | 0.050 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 2014 | 12 | 0.050 |
Why?
|
Insulin | 2 | 2014 | 346 | 0.050 |
Why?
|
Cell Polarity | 1 | 2019 | 14 | 0.040 |
Why?
|
Disease Progression | 2 | 2015 | 572 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2019 | 7 | 0.040 |
Why?
|
Thymus Gland | 1 | 2019 | 15 | 0.040 |
Why?
|
Hematopoiesis | 1 | 2019 | 34 | 0.040 |
Why?
|
Antibody Formation | 1 | 2019 | 39 | 0.040 |
Why?
|
Immunotherapy | 1 | 2019 | 69 | 0.040 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2018 | 2 | 0.040 |
Why?
|
Chemokine CCL5 | 1 | 2018 | 6 | 0.040 |
Why?
|
Lymph Nodes | 1 | 2019 | 92 | 0.040 |
Why?
|
Neurogenesis | 1 | 2018 | 14 | 0.040 |
Why?
|
Postoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
Micronucleus Tests | 1 | 2018 | 3 | 0.040 |
Why?
|
NF-kappa B | 1 | 2018 | 75 | 0.040 |
Why?
|
Stromal Cells | 1 | 2018 | 70 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 21 | 0.040 |
Why?
|
Thoracic Vertebrae | 1 | 2018 | 42 | 0.040 |
Why?
|
Neovascularization, Pathologic | 1 | 2018 | 81 | 0.040 |
Why?
|
Thorax | 1 | 2018 | 27 | 0.040 |
Why?
|
Lumbar Vertebrae | 1 | 2018 | 97 | 0.040 |
Why?
|
Lung Injury | 1 | 2018 | 64 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 208 | 0.040 |
Why?
|
Tongue | 1 | 2016 | 13 | 0.040 |
Why?
|
Bone Density | 1 | 2018 | 182 | 0.040 |
Why?
|
Reactive Oxygen Species | 1 | 2017 | 158 | 0.040 |
Why?
|
Microglia | 1 | 2016 | 48 | 0.040 |
Why?
|
Cells, Cultured | 1 | 2018 | 799 | 0.040 |
Why?
|
Reoperation | 1 | 2016 | 203 | 0.030 |
Why?
|
Patient Readmission | 1 | 2016 | 105 | 0.030 |
Why?
|
Platelet Activation | 1 | 2014 | 12 | 0.030 |
Why?
|
Platelet Function Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 81 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2015 | 37 | 0.030 |
Why?
|
Area Under Curve | 1 | 2014 | 84 | 0.030 |
Why?
|
Dogs | 1 | 2015 | 117 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2014 | 56 | 0.030 |
Why?
|
Erythrocebus patas | 1 | 2014 | 1 | 0.030 |
Why?
|
Codon | 1 | 2014 | 7 | 0.030 |
Why?
|
Leptin | 1 | 2014 | 66 | 0.030 |
Why?
|
Gene Targeting | 1 | 2014 | 17 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2014 | 42 | 0.030 |
Why?
|
Anticoagulants | 1 | 2014 | 120 | 0.030 |
Why?
|
Mice, Inbred CBA | 1 | 2013 | 6 | 0.030 |
Why?
|
Collagen | 1 | 2014 | 217 | 0.030 |
Why?
|
Brain Death | 1 | 2013 | 27 | 0.030 |
Why?
|
Cell Count | 1 | 2013 | 50 | 0.030 |
Why?
|
Species Specificity | 1 | 2013 | 84 | 0.030 |
Why?
|
Maternal-Fetal Exchange | 1 | 2013 | 5 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 531 | 0.030 |
Why?
|
bcl-Associated Death Protein | 1 | 2013 | 6 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2013 | 14 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 871 | 0.030 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2013 | 3 | 0.030 |
Why?
|
RANK Ligand | 1 | 2013 | 4 | 0.030 |
Why?
|
Propanolamines | 1 | 2013 | 11 | 0.030 |
Why?
|
Pituitary-Adrenal System | 1 | 2013 | 24 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 360 | 0.030 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2013 | 34 | 0.030 |
Why?
|
Thyroid Hormone Receptors alpha | 1 | 2012 | 1 | 0.030 |
Why?
|
Thyroid Hormone Receptors beta | 1 | 2012 | 2 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2013 | 28 | 0.030 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2013 | 36 | 0.030 |
Why?
|
Animal Experimentation | 1 | 2012 | 6 | 0.030 |
Why?
|
Epinephrine | 1 | 2013 | 41 | 0.030 |
Why?
|
Swine | 1 | 2013 | 201 | 0.030 |
Why?
|
Neoplasms | 1 | 2019 | 608 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 59 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2012 | 67 | 0.030 |
Why?
|
Proteinuria | 1 | 2013 | 57 | 0.030 |
Why?
|
Protein Transport | 1 | 2012 | 74 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2013 | 67 | 0.030 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 121 | 0.030 |
Why?
|
Autoantibodies | 1 | 2013 | 41 | 0.030 |
Why?
|
Coronary Angiography | 1 | 2013 | 136 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2013 | 64 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2013 | 128 | 0.030 |
Why?
|
Hemodynamics | 1 | 2013 | 148 | 0.030 |
Why?
|
Diet, Atherogenic | 1 | 2012 | 61 | 0.030 |
Why?
|
Cholecalciferol | 1 | 2012 | 21 | 0.030 |
Why?
|
Oxygen | 1 | 2013 | 139 | 0.030 |
Why?
|
Creatinine | 1 | 2013 | 173 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2012 | 148 | 0.030 |
Why?
|
Social Isolation | 1 | 2012 | 42 | 0.030 |
Why?
|
Base Sequence | 1 | 2012 | 240 | 0.030 |
Why?
|
Macaca | 1 | 2012 | 25 | 0.030 |
Why?
|
Haplorhini | 1 | 2012 | 64 | 0.030 |
Why?
|
Energy Intake | 1 | 2012 | 120 | 0.030 |
Why?
|
Mice, Nude | 1 | 2013 | 276 | 0.030 |
Why?
|
Histological Techniques | 1 | 2011 | 5 | 0.030 |
Why?
|
Anti-Mullerian Hormone | 1 | 2011 | 15 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 1 | 2011 | 19 | 0.030 |
Why?
|
Electrocardiography | 1 | 2016 | 562 | 0.030 |
Why?
|
Biopsy | 1 | 2012 | 241 | 0.030 |
Why?
|
Lung | 1 | 2013 | 233 | 0.030 |
Why?
|
Cholesterol | 1 | 2013 | 229 | 0.030 |
Why?
|
Mutation | 1 | 2014 | 466 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 189 | 0.030 |
Why?
|
Biomedical Research | 1 | 2012 | 153 | 0.020 |
Why?
|
Survival Rate | 1 | 2013 | 795 | 0.020 |
Why?
|
Papilloma | 1 | 2010 | 7 | 0.020 |
Why?
|
Phylogeny | 1 | 2010 | 58 | 0.020 |
Why?
|
Foot | 1 | 2010 | 40 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2010 | 22 | 0.020 |
Why?
|
Phosphopeptides | 1 | 2010 | 3 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2010 | 32 | 0.020 |
Why?
|
Hand | 1 | 2010 | 63 | 0.020 |
Why?
|
Protein Structure, Secondary | 1 | 2010 | 45 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2010 | 60 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2010 | 82 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2010 | 95 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2010 | 90 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2010 | 57 | 0.020 |
Why?
|
Fructosamine | 1 | 2009 | 5 | 0.020 |
Why?
|
Animal Feed | 1 | 2009 | 14 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2010 | 248 | 0.020 |
Why?
|
Protein Binding | 1 | 2010 | 199 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 836 | 0.020 |
Why?
|
Phosphorylation | 1 | 2010 | 225 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 125 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 241 | 0.020 |
Why?
|
Blotting, Western | 1 | 2010 | 281 | 0.020 |
Why?
|
Pilot Projects | 1 | 2011 | 469 | 0.020 |
Why?
|
Myositis | 1 | 2009 | 10 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 2009 | 41 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2009 | 42 | 0.020 |
Why?
|
Ovarian Follicle | 1 | 2009 | 23 | 0.020 |
Why?
|
Medroxyprogesterone | 1 | 2008 | 12 | 0.020 |
Why?
|
Vacuoles | 1 | 2008 | 3 | 0.020 |
Why?
|
Cytoplasmic Granules | 1 | 2008 | 6 | 0.020 |
Why?
|
Neutrophil Infiltration | 1 | 2008 | 9 | 0.020 |
Why?
|
Hypertrophy | 1 | 2008 | 26 | 0.020 |
Why?
|
Kidney | 1 | 2013 | 485 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2016 | 3712 | 0.020 |
Why?
|
Chromans | 1 | 2008 | 5 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2008 | 55 | 0.020 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 1 | 2007 | 3 | 0.020 |
Why?
|
Thiazolidinediones | 1 | 2008 | 47 | 0.020 |
Why?
|
Rabbits | 1 | 2008 | 185 | 0.020 |
Why?
|
United States | 1 | 2016 | 3604 | 0.020 |
Why?
|
Keratinocytes | 1 | 2007 | 26 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 212 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 641 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2009 | 747 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2008 | 708 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 1218 | 0.020 |
Why?
|